Intuitive Surgical built an entire surgical category and, for more than twenty years, owned it almost alone: a da Vinci system in roughly 11,400 hospitals worldwide, ~86% of revenue recurring through the instruments and services those systems consume, and 21% growth to a record $10.06 billion in 2025. In 2026 the question changed. The first genuine competitors won clearances, growth was guided lower, and the stock fell ~26% — forcing a re-pricing of one of medtech's largest and most profitable surgical-robotics franchises. This study takes that tension apart.

Source: Intuitive FY2025 results [4]; prior-year revenue from company filings. Headline financials are disclosed (Tier-1); market-share, valuation and forecast figures cited later are third-party estimates, labeled throughout.

The three decisive questions

Answer-first, but neutral: here is where the evidence stands and what is contested. Each links to the section that lays out both sides in full.

The bull and bear case, in brief

Neither column alone is the answer. Weighed together, the evidence leans toward slow share erosion and a mostly-cyclical growth dip, with the multiple genuinely contested — the closing weighing in the Forward View shows the work. Start with the Overview & Timeline, or jump to any section in the sidebar.

Independent case study · not affiliated with, endorsed by, or sponsored by ServiceNow, Inc. (NYSE: NOW) or any of its affiliates. A point-in-time research artifact, as of June 7, 2026. ServiceNow is public; headline financials are from SEC filings and earnings releases, while market-share figures and valuation multiples are third-party estimates that move with the market, labeled where used. See Methodology & Limitations.

Intuitive turned a U.S. military-funded research prototype into a 20-million-patient global platform and the default tool for minimally invasive soft-tissue surgery — and in 2025 handed the CEO role to a 29-year insider, days before its competitive landscape changed.

What it does

Intuitive Surgical designs, makes and services robotic systems for minimally invasive surgery. Its flagship da Vinci system lets a surgeon operate seated at a console, controlling wristed instruments and a 3D camera through small incisions. Around the system sit the consumables that actually make the money — EndoWrist instruments with programmed use limits, accessories, and multi-year service contracts. Two adjacent platforms extend the franchise: Ion, a robotic bronchoscope for minimally invasive lung biopsy, and the single-incision da Vinci SP. Cumulatively, da Vinci has been used in roughly 17 million procedures and Intuitive marks more than 20 million patients treated worldwide [45],[14].

How it got here

1. 1995
   Incorporated around SRI robotics IP
   Frederic Moll, John Freund and Robert Younge license surgical-robotics technology developed at SRI International (originally with U.S. military funding) and write the business plan for Intuitive Surgical Devices [10].
2. 1997–1999
   “Lenny” prototype, then Europe
   The SRI design is refined into a prototype (nicknamed after Leonardo da Vinci) and first marketed in Europe in 1999 while awaiting U.S. clearance [10].
3. 2000–2001
   IPO and first FDA clearances
   Intuitive raises $46M in its 2000 IPO; the FDA clears da Vinci for general laparoscopic surgery (2000) and prostatectomy (2001) — the procedure that drove early adoption [11].
4. 2019–2024
   Platform expansion: Ion and da Vinci 5
   Ion (robotic lung biopsy) launches and scales; in March 2024 the FDA clears the fifth-generation da Vinci 5 with Force Feedback and ~10,000× more computing power [12],[26].
5. Jun–Jul 2025
   da Vinci 5 goes international
   Japan clears da Vinci 5 (June 2025) and Europe grants the CE mark (July 2025), opening the platform's global ramp [43].
6. Jul 1, 2025
   CEO transition
   Dave Rosa becomes CEO; Gary Guthart moves to executive chair after 15 years leading the company [37].
7. Dec 2025
   The competitive set arrives
   Medtronic's Hugo wins its first U.S. clearance (urology); J&J files Ottava with the FDA; CMR and SS Innovations advance lower-cost systems [18],[20],[21].

Who runs it

In May 2025 Intuitive named president Dave Rosa chief executive, effective July 1, 2025; long-time CEO Gary Guthart became executive chair after 15 years in the role [37]. Rosa is the consummate insider — Intuitive's ninth employee, with 29 years at the company, who founded its endoluminal and single-port groups and helped create the Ion and da Vinci SP systems [38]. Analysts at Citi and RBC framed the handover as low-risk continuity rather than a strategic reset [39].

The surgical-robot systems market — roughly $11–14 billion today and forecast to roughly double by 2030 — is still a thin slice of a ~$94B minimally invasive surgery market. Most eligible procedures are not yet robotic, which is simultaneously Intuitive's growth runway and the prize drawing Medtronic, J&J and others in.

How big, and how fast

Third-party estimates of the surgical-robots market cluster around $11–12 billion in 2024, projected to roughly double by 2030 — one widely-cited estimate puts it at $27 billion (≈14.7% CAGR), though figures vary by firm [15]. That sits inside the much larger minimally invasive surgery market — about $94 billion in 2025, forecast to near $199 billion by 2030 as MIS displaces open surgery for its shorter stays and faster recovery [16]. Robotics is the fastest-growing slice of that shift.

Source: Grand View Research surgical-robot systems market [15]; MIS sizing from MarketsandMarkets [16]. Both are third-party estimates (Tier-3).

Structure: a concentrated category inside a fragmented one

Surgical robotics is unusually concentrated. Intuitive's systems were used in nearly 17 million procedures worldwide by 2024, an installed-base flywheel few medtech franchises match [45]. Geographically, North America holds over 50% of the surgical-robot market, while Asia-Pacific is the fastest-growing region — a split that matters because Intuitive's China exposure is both a growth lever and a tariff/competition risk (see Risks) [17]. The broader MIS value chain — open surgery, laparoscopy, robotics — remains fragmented, so robotics has years of share to take from non-robotic approaches.

Why penetration cuts both ways

Intuitive's economics are the textbook razor-and-blade: the da Vinci system is the razor, the per-procedure EndoWrist instruments and service contracts are the blades. In Q1 2026 ~86% of revenue was recurring — the source of both its quality and the right-to-repair criticism leveled at it.

The revenue engine

Each da Vinci placement seeds years of high-margin, recurring revenue. Hospitals build surgical workflows around the system, surgeons train on it, and every procedure consumes EndoWrist instruments that carry programmed use limits, plus accessories and a service contract [7]. In FY2025, instruments & accessories revenue was $5.08 billion (+19%) while systems revenue was $1.97 billion (+17%) — the blades out-earning the razors more than two-to-one [5]. The result is a business where ~86% of sales recur regardless of any single quarter's system orders [6].

Source: Intuitive FY2025 segment revenue [5],[4]; recurring share [6].

Why the installed base compounds

The model strengthens with scale: Q1 2026 da Vinci 5 placements rose to 232 (from 147 a year earlier), and Ion's installed base grew 22% to 1,041 systems — each new system widening the annuity of consumables and service [42]. Because revenue is tied to procedures performed, not one-time sales, growth is driven by surgical volume across a growing fleet rather than by selling the same hospital a new robot each year.

The model's double edge

Intuitive still holds ~60%+ of surgical robotics and performs an estimated ~83% of U.S. robotic urology procedures — but in a single quarter (Q4 2025) Medtronic's Hugo was cleared, J&J filed Ottava, and two low-cost rivals advanced. The monopoly era is ending; the question is how fast share actually moves.

The incumbent's position

By volume and installed base, Intuitive remains dominant: an estimated 60%+ share of the surgical-robotics market and a far larger share of multiport soft-tissue procedures [40]. In urology — the category Medtronic just entered — analysts estimate Intuitive performs about 190,000 of roughly 230,000 annual U.S. procedures (~83%) [19]. That lead is built on the installed base, surgeon training, and a two-decade clinical-evidence head start (see Strategy & Moats).

The challengers

Lower-cost systems list at roughly $0.6–1.2M (Mantra) and $0.75–1M (Versius), well below a da Vinci, and Chinese-made laparoscopic robots outsold imports in China's 2025 public tenders [22].

Five Forces — pressure is rising, not yet overwhelming

Click a force to see the evidence behind each rating.

Positioning: premium-broad vs. value and niche

How threatening is it, really?

Intuitive's moat is an ecosystem, not a single patent: ~11,400 installed systems, trained surgeons, captive consumables, and twenty years of clinical evidence rivals must replicate. Its strategy is to deepen that moat (da Vinci 5, Ion, SP) faster than competition and right-to-repair pressure can erode it.

Where the advantage comes from

The durable edge is the combination of an installed base of 11,000+ systems, deep surgeon training, switching costs baked into hospital workflows, and a roughly two-decade regulatory and clinical-evidence lead — an ecosystem a new entrant cannot buy, only rebuild over years [24]. Every procedure also adds to a proprietary corpus of surgical data that the da Vinci 5's ~10,000× compute leap is designed to turn into vision, analytics and coaching features — a potential data moat layered on the hardware one.

The platform-expansion playbook

Rather than rely on da Vinci alone, Intuitive is widening the franchise into adjacent procedures:

• da Vinci 5 — the upgrade cycle itself is a moat: Force Feedback and new AI/vision features give surgeons reasons to stay, and the international ramp (Europe, Japan) extends it globally [24].
• Ion (robotic lung biopsy) — procedures grew ~51% in 2025 to ~144,000, with installed base up ~24% (now ~1,000 systems) — opening diagnosis-to-treatment pathways feeding da Vinci surgery [26],[42].
• da Vinci SP (single-port) — Intuitive won new indications (inguinal hernia, gallbladder, appendectomy) in 2025, extending into single-incision surgery [25],[21].

SWOT

Stated vs. revealed strategy

On a robotics basis Intuitive is the clear leader; on a corporate basis its rivals dwarf it — Medtronic and J&J are ~$30B+ diversified medtechs that can fund a robotics war from other businesses. The honest read is directional: Intuitive leads the category, but its challengers are not financially fragile.

Robotics positioning vs. peers

Each cell is sourced; corporate financials for the diversified peers are not separately broken out for robotics.

The price gap that defines the contest

Source: rival pricing from R2 Surgical [22]; da Vinci figure derived/estimated, labeled as such.

2025 was a record year — $10.06B revenue (+21%), ~$2.85B GAAP net income — and Q1 2026 accelerated to +23% with a ~39% adjusted operating margin. The blemish: non-GAAP gross margin slipped to ~67% from 69.1% as tariffs and mix weighed.

The top line

Full-year 2025 revenue reached $10.06 billion, up 21% from $8.35 billion in 2024 [4]. The mix is recurring-led: instruments & accessories $5.08B (+19%) and systems $1.97B (+17%), with service making up most of the balance (see Business Model) [5]. GAAP net income totaled roughly $2.85 billion across the four quarters [27]. Momentum carried into 2026: Q1 revenue of $2.77 billion (+23%), with adjusted operating margin at ~39% and EPS up 38% [1],[9].

The da Vinci 5 ramp

Beneath the revenue is a hardware refresh: da Vinci 5 placements climbed through 2025, peaking at a record 303 units in Q4 2025 (of 532 total systems placed), before the usual first-quarter seasonality [46],[3]. The chart shows the quarterly da Vinci 5 placement curve.

Source: Intuitive Q4 2025 [46] and Q1 2026 [3] releases (disclosed unit counts).

The pressure point: gross margin

The one clearly negative trend is margin. Non-GAAP gross margin fell to a 67–67.5% range in 2025, from 69.1% in 2024, including an estimated 0.7 percentage points from tariffs [8]. With significant China manufacturing exposure, trade policy is a direct cost input — management projected a ~$165M tariff hit for 2025 (see Risks). Operating leverage and pricing have so far kept operating margins near 39%, but the gross-margin glide path is the number bears watch most closely.

Run the number: how long to grow into the multiple

A back-of-envelope implied-expectations check (our arithmetic, illustrative — not a forecast): divide the ~$149B market cap [34] by ~$2.85B of 2025 GAAP net income [27] and ISRG trades at about 52× trailing earnings. Hold the price flat and compound earnings at the 2026 procedure-guidance band of 13.5–15.5% [33] — assuming earnings roughly track procedures — and after five years earnings reach ~$5.4–5.9B, leaving today's price at ~25–28× 2030 earnings, roughly Medtronic's own five-year average multiple of ~28× [49]. Read plainly: the current price pre-pays for about five years of guidance-pace growth before ISRG reaches a diversified-medtech valuation. If growth slips to ~10%, the same walk ends near ~$4.6B and ~32× — which is why the deceleration question, not the competition headlines, carries the valuation debate (see Forward View).

Reading the financials

None of these is, on its own, an existential threat — but they landed together in 2026: GLP-1 drugs shrinking bariatric volumes, tariffs denting margin, right-to-repair litigation over the consumables model, and sentiment shocks (competition, an OpenAI-robots scare) that helped knock the stock down ~26%.

1. GLP-1 drugs are eroding a (small) procedure segment

For six consecutive quarters, U.S. bariatric volumes fell in the high single digits — a trend Intuitive directly attributes to GLP-1 weight-loss drugs [28]. The macro backdrop is stark: between 2022 and 2023, U.S. bariatric surgery rates fell 25.6% as GLP-1 prescriptions rose 132.6%, per a Harvard/Brigham study, with one forecaster projecting a further 15% decline by 2034 [29]. The mitigant: bariatric is now under 3% of U.S. da Vinci procedures, so the direct hit is contained — though it raises a broader question about whether drugs can substitute for surgery elsewhere [28].

2. Tariffs and China exposure compress margin

Intuitive manufactures and sources significantly through China, making it unusually exposed to trade policy. Management projected a ~$165M tariff hit in 2025 — roughly 1.7 points of gross-margin headwind — driven mainly by US–China tariffs [30]. The mitigant: bilateral rates eased during 2025, letting Intuitive trim the expected impact, and the company has pricing and supply-chain levers; but China is also where lower-cost domestic rivals are strongest, compounding the exposure.

3. The consumables model is a legal target

The razor-and-blade model that drives ~86% recurring revenue is also a litigation magnet. Surgical Instrument Service Co. (SIS) sued in 2021, alleging Intuitive monopolizes EndoWrist servicing via programmed use limits and repair restrictions; SIS argued it could refurbish instruments at 55–70% of new cost, saving hospitals tens to hundreds of millions [32]. In 2024 a federal judge granted judgment as a matter of law for Intuitive, citing the Epic v. Apple aftermarket standard — a clear win [31]. But a separate, larger case remains live: in In re Da Vinci Surgical Robot Antitrust Litigation (N.D. Cal.), the court in March 2025 certified a class of direct purchasers who bought da Vinci service and EndoWrist products from May 21, 2017 to Dec. 31, 2021, on allegations Intuitive unlawfully tied the robot to its own maintenance and EndoWrist servicing under Sherman Act §§1–2 [47].

4. Competition and sentiment shocks

The arrival of Medtronic Hugo and J&J Ottava (see Competitive Landscape) is the structural risk. Layered on top in 2026 was a sentiment shock: OpenAI's late-May move into building robots "stoked fears" the AI giant could one day reach surgical robotics — a fear several analysts called overdone given Intuitive's installed-base moat and regulatory lead, but which still contributed to the drawdown [41].

Risk vs. mitigant, side by side

The debate reduces to three variables: how fast procedure growth decelerates, whether new rivals actually take share, and what multiple the market pays. 2026 guidance of ~13.5–15.5% da Vinci procedure growth (down from ~17%) is the number that anchors all three.

The set-up

For 2026 Intuitive guided da Vinci procedure growth of 13.5–15.5% (worldwide ~13–15%), a step down from ~17%+ in 2025 [33]. The stock has already re-priced: ISRG fell ~26% in 2026, from above $600 in January to about $422, trimming the market cap to ~$149B at a trailing P/E near 50 [34]. Valuation views diverge sharply — some DCF models imply intrinsic value as low as ~$196, while bulls see fair value up to ~$532, and the Street's average target sits roughly a third above the price [35],[36].

What the price assumes

Date-stamped, because all of it moves: at ~$422, ISRG trades at ~50× trailing earnings (49.98 as of June 10, 2026) — about 30% below its own five-year average of ~71× [48], yet still more than double Medtronic's ~21.6× (whose five-year average is ~28×) [49]. Trailing growth was +21% in 2025 [4]; guidance implies ~13.5–15.5% procedure growth for 2026 [33]. The implied read: the de-rating has moved ISRG from priced-for-perfection to priced-for-excellence — a ~50× multiple holds only if mid-teens compounding on ~86% recurring revenue persists for years. That is the bar both the bull and the bear cases are measured against; it is not a buy or sell signal.

Three scenarios to weigh

Sources: 2026 guidance [33]; valuation and drawdown [34],[35]; analyst consensus [36]. Scenarios are illustrative framings, not predictions.

The weighing

On whether competition converts clearances into share: the evidence leans toward slow erosion, not a crack (medium confidence). The controlling evidence is Intuitive's ~83% of U.S. robotic urology — the one category Hugo has actually entered, on a 137-procedure submission cohort [19] — and an installed base of 11,395 systems still growing 12% a year [3], which outweighs the "there is now choice" framing [44] because a cleared rival must still displace trained surgeons and hospital workflows one site at a time [24]. The strongest surviving counter-argument: two deep-pocketed incumbents (Hugo cleared, Ottava filed) plus sub-$1.2M systems are attacking the premium and value ends at once [18],[20],[22]. What would flip this reading: Hugo or Ottava winning multi-specialty U.S. clearances while Intuitive's quarterly system placements turn negative year over year in 2026–27 releases; or da Vinci procedure growth printing below the 13.5% guidance floor at the Q4 2026 report [33]. Pre-mortem: if this looks wrong in two years, the most likely reason is underestimating how fast "good enough at a third of the price" moves price-sensitive and emerging markets [22] — or, on the other side, overrating the challengers and missing that da Vinci 5's compute and data layer widened the moat faster than they could close it [12].

On whether the deceleration is cyclical or structural: the evidence leans cyclical — a penetration story with one drug-shaped dent (medium confidence). The controlling evidence is that bariatric, the only segment GLP-1 drugs have demonstrably hit, is under 3% of U.S. da Vinci procedures [28], and worldwide procedures still grew ~17% in Q1 2026 with Ion up ~39% [2] inside an MIS market projected to roughly double by 2030 [16] — which outweighs six straight quarters of bariatric decline because the drag has stayed segment-confined while the rest of the portfolio compounds. The strongest surviving counter-argument: the macro data are stark — U.S. bariatric surgery fell 25.6% in a single year as GLP-1 prescriptions rose 132.6% [29] — proof a drug can shrink a surgical category outright. What would flip this reading: management attributing softness in a second procedure category to GLP-1s on a 2026–27 earnings call, or FY2026 da Vinci procedure growth landing below the guided 13.5–15.5% band at the early-2027 report [33]. Pre-mortem: if this looks wrong in two years, the most likely reason is treating GLP-1 substitution as contained when it was a template — or, on the bull side, underweighting the da Vinci 5 upgrade cycle and SP/Ion expansion now compounding [25],[26].

On whether a ~50× multiple survives: genuinely contested — the evidence deadlocks. What deadlocks it is the spread on the same disclosed numbers: a published DCF pegs intrinsic value near $196 against a ~$412 price [35], while the 19-analyst consensus target sits ~33% above the price [36]. The demand the multiple makes is checkable, though: at ~$149B over ~$2.85B of 2025 earnings (~52×) [34],[27], even five years of guidance-pace compounding leaves today's price at roughly 25–28× 2030 earnings (the arithmetic is in Financials). What would flip this toward the bears: non-GAAP gross margin breaking below ~66% (from 67–67.5% in 2025 [8]) or procedure growth below ~12% in any 2026 quarter; toward the bulls: 2026 beating the 15.5% top of guidance with margin stabilizing [33]. Pre-mortem: if this looks wrong in two years, bulls will most likely have paid a monopoly multiple for a duopoly — or, on the other side, bears will have sold a compounder into a sentiment shock analysts already called overdone [41].

How it was researched

This study was produced through fan-out web research: dozens of searches and source fetches, with each load-bearing claim traced to a source actually read during the research run. Sources are tiered — Tier 1 (primary: Intuitive Surgical earnings releases and SEC 8-K exhibits, official newsroom statements, a competitor's own FDA-clearance release), Tier 2 (reputable secondary: MedTech Dive, MassDevice, Medical Design & Outsourcing, Citeline Medtech Insight, The Motley Fool, Yahoo Finance), and Tier 3 (tertiary/analyst/market-data: market-sizing firms, valuation aggregators, an investor-newsletter deep-dive, Wikipedia for company history). The full list, with tier and stance, is on the Sources page.

A note on primary-source access

Intuitive is a U.S. public company, so its hard financials are well-disclosed. SEC.gov blocks automated fetching, so some primary figures are cited via the company's investor newsroom and machine-readable filings and cross-checked against reputable secondary coverage of the same releases. The underlying revenue, segment, margin, procedure and system-placement numbers are company disclosures, not estimates.

Disclosed vs. estimated

Disclosed (Tier-1): total and segment revenue, gross margin, system placements, installed base, procedure growth, and the CEO transition — all from Intuitive's releases. Derived: the ~$2.85B full-year 2025 GAAP net income is the sum of disclosed quarterly figures. Estimated / third-party: the ~60%+ market share, ~83% urology share, market-size and CAGR projections, the ~$2M da Vinci system price (implied, not disclosed), valuation metrics (the ~$422 price, ~$149B market cap, ~50× P/E and DCF intrinsic values all move with the market), and the ~$165M tariff and Q1'26 ~39% margin / +38% EPS figures (secondary summaries). These are labeled where used. Competitor and market figures come from different methodologies and periods, so cross-company comparisons are directional.

Frameworks used

Pyramid Principle (answer-first executive summary), a dated timeline, Porter's Five Forces, a 2×2 positioning map, a razor-and-blade business-model and value-chain teardown, a SWOT, peer comparables, and bull/base/bear scenarios. Each is applied to the evidence on both sides; where the weight of evidence supports a lean, the study states it — with a confidence level and the tripwires that would change it (see the Forward View's closing weighing).

Neutrality & balance

The goal is an evidence-led weighing, not advocacy. Positive claims (dominance, recurring revenue, accelerating growth) and critical ones (competition, GLP-1 erosion, tariffs, valuation, right-to-repair litigation) are held to the same sourcing standard, and critical claims are attributed to named outlets or court rulings rather than stated as fact. An automated balance check records the stance mix (supporting / critical / neutral) per section. The descriptive Overview and benchmarking Peer Comparison sections are mostly neutral by design; Financials leans supporting and Risks leans critical by nature, with the opposing view kept present in the prose of each.

Independence

This is an independent research artifact, not affiliated with, endorsed by, or sponsored by Intuitive Surgical, Inc. or any affiliate. No company provided information or review.

Independent case study · not affiliated with, endorsed by, or sponsored by ServiceNow, Inc. (NYSE: NOW) or any of its affiliates. A point-in-time research artifact, as of June 7, 2026. ServiceNow is public; headline financials are from SEC filings and earnings releases, while market-share figures and valuation multiples are third-party estimates that move with the market, labeled where used. See Methodology & Limitations.

Tier 1 = primary/authoritative (Intuitive earnings releases & SEC 8-K exhibits, official newsroom statements, a competitor's FDA-clearance release). Tier 2 = reputable secondary (MedTech Dive, MassDevice, Medical Design & Outsourcing, Citeline Medtech Insight, The Motley Fool, Yahoo Finance). Tier 3 = tertiary/analyst/market-data (market-sizing firms, valuation aggregators, an investor newsletter, Wikipedia) — used for colour or as labeled estimates.

Independent case study · not affiliated with, endorsed by, or sponsored by ServiceNow, Inc. (NYSE: NOW) or any of its affiliates. A point-in-time research artifact, as of June 7, 2026. ServiceNow is public; headline financials are from SEC filings and earnings releases, while market-share figures and valuation multiples are third-party estimates that move with the market, labeled where used. See Methodology & Limitations.